This activity will present recent updates from the NCCN Bladder Guidelines for all stages of disease including but not limited to, Locally Advanced and Metastatic Disease, and will represent a substantial restructuring of the principles of systemic therapy for patients with this disease (ref. NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines ] Bladder Cancer Version 1.2025-March 25, 2025).
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 1301 Virginia Dr
Pricing
79% of listed courses are free
11 of 14 courses listed here are free.
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Regularly Scheduled Series
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedApr 30, 2026
-
Last day to claim creditJan 1, 2027 3 months left
-
Medscape, LLC Redefining Locally Advanced/Metastatic Urothelial Carcinoma Care: The Impact of Updated Guidelines on the Community Oncology Practice
-
Answers in CME Inc. (AiCME) Advancing Holistic First-Line Care in Advanced Urothelial Carcinoma: Guideline-Based Strategies and Best Practices in AE Management
-
Plexus Communications +1 Practice-Changing Advancements in the First-Line Treatment of Advanced and Metastatic Urothelial Cancer: Optimizing the Care
-
AXIS Medical Education, Inc. Chairman’s Perspective: Reframing First-Line and Sequenced Care in Advanced Urothelial Carcinoma: Clinical Implications of the Updated NCCN Guidelines
-
AXIS Medical Education, Inc. HER2 in Solid Tumors: From Pathology to Personalized Treatment Plans
-
AXIS Medical Education, Inc. Advancing ADT in HSPC: Interprofessional Intensification Strategies Reshaping Care
